Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sylvain Picard is active.

Publication


Featured researches published by Sylvain Picard.


Developmental Cell | 2004

The Atypical PKC-Interacting Protein p62 Is an Important Mediator of RANK-Activated Osteoclastogenesis

Angeles Duran; Manuel Serrano; Michael Leitges; Juana M. Flores; Sylvain Picard; Jacques P. Brown; Jorge Moscat; Maria T. Diaz-Meco

The atypical PKCs (aPKCs) have been implicated genetically in at least two independent signaling cascades that control NF-kappa B and cell polarity, through the interaction with the adapters p62 and Par-6, respectively. P62 binds TRAF6, which plays an essential role in osteoclastogenesis and bone remodeling. Recently, p62 mutations have been shown to be the cause of the 5q35-linked Pagets disease of bone, a genetic disorder characterized by aberrant osteoclastic activity. Here we show that p62, like TRAF6, is upregulated during RANK-L-induced osteoclastogenesis and that the genetic inactivation of p62 in mice leads to impaired osteoclastogenesis in vitro and in vivo, as well as inhibition of IKK activation and NF-kappa B nuclear translocation. In addition, RANK-L stimulation leads to the inducible formation of a ternary complex involving TRAF6, p62, and the aPKCs. These observations demonstrate that p62 is an important mediator during osteoclastogenesis and induced bone remodeling.


The Journal of Steroid Biochemistry and Molecular Biology | 2000

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.

Céline Martel; Sylvain Picard; Virgile Richard; Alain Bélanger; Claude Labrie; Fernand Labrie

Some undesirable effects are associated with chronic estrogen and progestin administration used to prevent bone loss in postmenopausal women, thus leading to poor compliance and the need for improved therapeutic and preventive agents. We have thus studied the ability of the new antiestrogen EM-800 (SCH 57050) to prevent bone loss and lower serum cholesterol levels and compared its effects with those of raloxifene. Ovariectomized (OVX) female rats were treated by oral gavage for 37 weeks with increasing daily doses (0.01, 0.03, 0.1, 0. 3 or 1 mg/kg) of EM-800 or raloxifene. At 35 weeks after OVX, lumbar spine bone mineral density (BMD) was 19% lower than in intact animals (P<0.01), while the OVX animals given EM-800 or raloxifene had 90-93 and 85-90%, respectively, of the BMD values observed in intact rats. Similar effects were observed on femoral BMD. Bone histomorphometry measurements were performed on proximal tibia. At the 0.01 mg/kg dose, EM-800 prevented the effect of OVX on TBV by 34% (P<0.01), while raloxifene had no detectable effect. Treatment with 1 mg/kg EM-800 and raloxifene resulted in, respectively, 68% (P<0.01) and 64% (P<0.01) prevention of the OVX-induced decrease in TBV. In addition, the administration of 0.01 and 0.03 mg/kg EM-800 caused, respectively, 54% (P<0.01) and 56% (P<0.01) inhibitions of serum cholesterol levels, while raloxifene administered at the same doses caused, respectively, 24% (P<0.01) and 41% (P<0.01) decreases of the value of the same parameter. At the highest doses used (0.1-1 mg/kg), both compounds lowered serum cholesterol levels by approximately 65% (P<0.01). No stimulatory effect of EM-800 was observed on the endometrial epithelial cells at doses up to 1 mg/kg, while hypertrophy of uterine epithelium was observed with raloxifene. EM-800 and raloxifene achieve the same degree of effectiveness on bone and serum cholesterol at higher doses, but EM-800 is at least three to ten times more potent than raloxifene at lower concentrations and has no stimulatory effect on uterine epithelium. The present data show the potent effect of EM-800 preventing bone loss and lower serum cholesterol levels without the negative effect on the endometrium, thus suggesting the particular interest of this new fully tissue-specific selective estrogen receptor modulator.


Biology of Reproduction | 2001

Effect of vasectomy on P34H messenger ribonucleic acid expression along the human excurrent duct : A reflection on the function of the human epididymis

Christine Légaré; Michel Thabet; Sylvain Picard; Robert Sullivan

Abstract Sperm surface proteins involved in fertilization can be added or modified during epididymal transit. P34H, a human epididymal-sperm protein, appears on the sperm acrosomal cap in the distal caput-proximal corpus epididymis. In previous studies, it was shown that P34H is present on spermatozoa in men of proven fertility, is absent in 50% of men presenting with idiopathic infertility, and that a high proportion of men with normospermic vasovasectomy produce spermatozoa deficient in this sperm surface protein. P34H mRNA was expressed in the principal cells of the epididymis of normal men, predominantly in the corpus region. Recently, results coming from the assisted reproductive technologies have questioned the importance of the human epididymis in sperm maturation. In order to understand the effect of obstruction on the physiological state of the human epididymis and its function in sperm maturation, we have analyzed the expression of P34H mRNA at the level of the vas deferens and along the epididymis of normal and vasectomized men. In situ hybridization experiments showed that obstruction of the vas deferens alters the pattern of P34H mRNA expression compared with the tract of normal tissues. The P34H transcript was detected in the proximal caput epididymis of vasectomized men at a much higher intensity than that observed in the same region of normal tissues, being restricted to the principal cells of the epididymal epithelium. Compared with the normal duct, the lumen of vasectomized men was distended throughout the duct and the height of the epithelium was maximal in the caput. P34H mRNA was detectable in vas deferens, was not affected by vasectomy, and a 912-base pair P34H transcript was restricted to the epithelial cells of the vas deferens. Thus, using P34H as a marker, these results show that vasectomy alters the pattern of gene expression along the human epididymis, and suggest that the vas deferens can be a major contributor to sperm maturation in certain situations.


Anatomical Record-advances in Integrative Anatomy and Evolutionary Biology | 2008

Histomorphometric and Densitometric Changes in the Femora of Spinal Cord Transected Mice

Sylvain Picard; Nicolas P. Lapointe; Jacques P. Brown; Pierre A. Guertin

Spinal cord injury (SCI) leads generally to significant bone tissue loss within a few months to a few years post–trauma. Although, increasing data from rat models are available to study the underlying mechanisms of SCI‐associated bone loss, little is known about the extent and rapidity of bone tissue changes in mouse models of SCI. The objectives are to characterize and describe quantitatively femoral bone tissue changes during 1 month in adult paraplegic mice. Histomorphometric and densitometric measurements were performed in 3‐ to 4‐month‐old CD1 mice spinal cord transected at the low‐thoracic level (Th9/10). We found a general decrease in bone volume (−22%), trabecular thickness (−10%), and trabecular number (−14%) within 30 days post‐transection. Dual‐energy X‐ray absorptiometric measurements revealed no change in bone mineral density but a significant reduction (−14%) in bone mineral content. These results show large structural changes occurring within only a few weeks post–spinal cord transection in the femora of adult mice. Given the increasing availability of genetic and molecular research tools for research in mice, this murine model may be useful to study further the cellular and molecular mechanisms of demineralization associated with SCI. Anat Rec, 291:303–307, 2008.


Laboratory Investigation | 2011

Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout

Isabelle Allaeys; Daniel Rusu; Sylvain Picard; Marc Pouliot; Pierre Borgeat; Patrice E. Poubelle

Bone destruction in chronic gout is correlated with deposits of monosodium urate (MSU) crystals. Bone with MSU tophi were histopathologically shown to have altered remodeling and cellular distribution. We investigated the impact of neutrophils in bone remodeling associated with MSU and demonstrated that neutrophils, through elastase localized at their surface, induced retraction of confluent osteoblasts (OBs) previously layered on calcified matrix. This OB retraction allowed osteoclasts to resorb cell-free areas of the matrix. This neutrophil effect was concentration dependent and time dependent and required direct contact with OBs. Exposure of OBs to MSU greatly promoted neutrophil adherence to OBs. Neutrophil membrane at the contact zone with OBs showed concentrated fluorescence of dye PKH-67, indicating a cellular contact. Neutrophil–OB interaction increased the survival of neutrophils, reduced their release of lactoferrin in presence of MSU and did not change OB-mediated mineralization. The adhesion of neutrophils to OBs was heterotypic through neutrophil CD29/CD49d and OB-fibronectin peptide CS1. Leukotriene B4 (LTB4) and platelet-activating factor (PAF) were also involved in neutrophil adherence to OBs, as shown by the blocking effect of selective LTB4 and PAF receptor antagonists, and a cytosolic phospholipase A2α (cPLA2α) inhibitor. Blockade of CD49d/CS1 and inhibition of the cPLA2α had subadditive effects, reducing by 60% the adherence of neutrophils to OBs. Taken together, these data showed that neutrophil adhesion to MSU-activated OBs was mediated by the β1 integrin CD29/CD49d-fibronectin peptide CS1 receptors and cPLA2α-derived metabolites and impacts on OB and osteoclast functions. These interactions could be involved in the local bone remodeling process of gout.


Journal of Bone and Mineral Metabolism | 2018

High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats

Sarah-Kim Bisson; Roth-Visal Ung; Sylvain Picard; Danika Valade; Mohsen Agharazii; Richard Larivière; Fabrice Mac-Way

A link between vascular calcification and bone anomalies has been suggested in chronic kidney disease (CKD) patients with low bone turnover disease. We investigated the vascular expression of osteocyte markers in relation to bone microarchitecture and mineralization defects in a model of low bone turnover CKD rats with vascular calcification. CKD with vascular calcification was induced by 5/6 nephrectomy followed by high calcium and phosphate diet, and vitamin D supplementation (Ca/P/VitD). CKD + Ca/P/VitD group (n = 12) was compared to CKD + normal diet (n = 12), control + normal diet (n = 8) and control + Ca/P/VitD supplementation (n = 8). At week 6, tibia, femurs and the thoracic aorta were analysed by Micro-Ct, histomorphometry and for expression of osteocyte markers. High Ca/P/VitD treatment induced vascular calcification only in CKD rats, suppressed serum parathyroid hormone levels and led to higher sclerostin, DKK1 and FGF23 serum levels. Expression of sclerostin, DKK1 and DMP1 but not FGF23 were increased in calcified vessels from CKD + Ca/P/VitD rats. Despite low parathyroid hormone levels, tibia bone cortical thickness was significantly lower in CKD + Ca/P/VitD rats as compared to control rats fed a normal diet, which is likely the result of radial growth impairment. Finally, Ca/P/VitD treatment in CKD rats induced a bone mineralization defect, which is likely explained by the high calcitriol dose. In conclusion, Ca/P/VitD supplementation in CKD rats induces expression of osteocyte markers in vessels and bone mineralisation anomalies. Further studies should evaluate the mechanisms of high dose calcitriol-induced bone mineralisation defects in CKD.


Journal of Bone and Mineral Research | 2018

Deletion of the Fanconi Anemia C Gene in Mice Leads to Skeletal Anomalies and Defective Bone Mineralization and Microarchitecture: FANCONI ANEMIA C GENE DELETION LEADS TO SKELETAL DEFECTS

Mélody Mazon; Jacinthe Julien; Roth-Visal Ung; Sylvain Picard; Dounia Hamoudi; Rose Tam; Jessica Filiatrault; Jérôme Frenette; Fabrice Mac-Way; Madeleine Carreau

Fanconi anemia (FA) is a rare genetic disorder associated with a progressive decline in hematopoietic stem cells leading to bone marrow failure. FA is also characterized by a variety of developmental defects including short stature and skeletal malformations. More than half of children affected with FA have radial‐ray abnormalities, and many patients have early onset osteopenia/osteoporosis. Although many Fanconi anemia genes have been identified and a molecular pathway defined, the underlying mechanism leading to bone defects remains elusive. To understand the role of FA genes in skeletal development and bone microarchitecture, we evaluated bone physiology during embryogenesis and in adult FancA‐ and FancC‐deficient mice. We found that both FancA‐/‐ and FancC‐/‐ embryos have abnormal skeletal development shown by skeletal malformations, growth delay, and reduced bone mineralization. FancC‐/‐ adult mice present altered bone morphology and microarchitecture with a significant decrease in cortical bone mineral density in a sex‐specific manner. Mechanical testing revealed that male but not female FancC‐/‐ mice show reduced bone strength compared with their wild‐type littermates. Ex vivo cultures showed that FancA‐/‐ and FancC‐/‐ bone marrow–derived mesenchymal stem cells (BMMSC) have impaired differentiation capabilities together with altered gene expression profiles. Our results suggest that defective bone physiology in FA occurs in utero and possibly results from altered BMMSC function. These results provide valuable insights into the mechanism involved in FA skeletal defects.


Human Genetics | 2015

Detection of SQSTM1/P392L post‑zygotic mutations in Paget's disease of bone

Sabrina Guay-Bélanger; Sylvain Picard; Edith Gagnon; Jean Morissette; Ethel S. Siris; Philippe Orcel; Jacques P. Brown; Laëtitia Michou


Annales De Pathologie | 2005

Caractérisation de la perte osseuse chez la souris adulte paraplégique : étude histomorphométrique et biomécanique

Sylvain Picard; Jacques P. Brown; J. Frenette; S. Jean; Pierre A. Guertin


Investigational New Drugs | 2018

Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model

Martin Perreault; René Maltais; Jenny Roy; Sylvain Picard; Ion Popa; Nicolas Bertrand; Donald Poirier

Collaboration


Dive into the Sylvain Picard's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Juana M. Flores

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Manuel Serrano

Catalan Institution for Research and Advanced Studies

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge